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INTRODUCTION 
 
Signaling pathways that are fundamental to 
development and tissue differentiation are usually 
found to participate in the pathogenesis of human 
cancer [1]. For example, Hedgehog, Wnt, Notch, and 
TGF-β pathways were found to play critical roles in 
both processes. These pathways involve ligand-
receptor interactions which initiate signal transduction 
that results in modulation of a set of downstream genes 
that mediate the ultimate functions of a specific 
pathway. However, aberrant activation of these 
signaling pathways may confer an advantage to tumor 
cells for growth in the host environment. The role of an 
aberrant Notch signaling pathway in human cancer is 
well illustrated in T-cell acute lymphocytic leukemia 
(T-ALL). Activating point mutations occur in more 
than 50% of T-ALL cases, and interstitial deletions of 
the extracellular portion of human Notch1 occur in 
another 10% due to chromosomal translocation [2, 3]. 
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ABSTRACT: 
Ovarian serous carcinoma is a highly aggressive neoplastic disease in women. Our 
previous studies have demonstrated Notch3 gene amplification and upregulation in 
many ovarian serous carcinomas and Notch pathway activity contributed to drug 
resistance. Among different Notch3 ligands, Jagged1 is most dominant in ovarian 
cancer, and Notch3 pathway activity correlated with Jagged1 expression level in 
ovarian carcinoma tissues. In this study, we found that Jagged1 expression depended 
on Notch3 pathway activation. Knockdown of either Notch3 or RBPjk, a Notch-
interacting transcription factor critical in Notch signaling, suppressed Jagged1 
expression in ovarian cancer cells. Moreover, Jagged1 expression was upregulated in 
human ovarian surface epithelial cells after ectopic expression of Notch3 intracellular 
domain and was upregulated in mouse epithelial cells isolated from Notch3-inducible 
mice after induction. We also found that inhibition of Wnt/β-catenin signaling 
reduced Jagged1 expression, and co-administration of shRNAs targeting both Notch3 
and  β-catenin reduced Jagged1 expression much more than targeting either 
individual gene. Taken together, our data suggested a positive regulatory loop 
between Notch3 and its ligand, Jagged1, in ovarian cancer cells. In addition, Wnt/β-
catenin pathway activation also up-regulated Jagged1. Both mechanisms may sustain 
Notch3 signaling in ovarian cancer cells and contribute to the pathogenesis of ovarian 
carcinoma.   
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Those molecular genetic alterations result in the 
dysregulated expression of an oncogenic intracellular 
form of Notch1 [4].   
By analyzing genome-wide DNA copy number 
changes in primary ovarian serous carcinoma, the most 
aggressive type of gynecologic cancer [5], we have 
identified a relatively frequent amplification located on 
chr19p13.12, which harbors Notch3  [6]. We have 
focused on characterizing this gene because, as 
compared to other co-amplified genes, Notch3 mRNA 
was most significantly up-regulated in amplified 
tumors. Notch3 (mRNA as well as protein) was found 
to be over-expressed in more than 50% of high-grade 
tumors as compared to ovarian surface epithelium. 
Recently, we have demonstrated that Notch3 
expression is associated with recurrence post-
chemotherapy, probably as a result of upregulation of 
an ATP-dependent transporter gene, ABCB1,  and 
several embryonic stem cell markers [7]. 
In order to determine which Notch ligand was most 
prevalent in ovarian cancer, we employed gene 
expression profiling of all known Notch ligands and 
found that Jagged1 was the primary Notch3 ligand in 
ovarian carcinoma. We observed a significant 
correlation between Jagged1 expression and nuclear 
localization of the intracellular cytoplasmic domain of 
Notch3 (NICD3) in ovarian serous carcinoma tissues 
[8]. Moreover, we found that in ovarian cancer cells, 
Notch3 could be co-immunoprecipitated with Jagged1 
[8], and ectopic expression of NICD3 could partly 
rescue the growth-inhibitory effect produced by 
Jagged1 withdrawal [8]. These findings suggested a 
critical role for Jagged1-Notch3 signaling in supporting 
the growth and progression of ovarian cancer. While 
molecular genetic changes such as translocation and 
activating mutations provide the mechanism for 
constitutively activating the Notch pathway, it is not 
known how overexpression of Notch due to gene 
amplification or epigenetic upregulation sustains 
pathway activation. In the absence of structural 
alterations, increased protein levels of receptor alone 
may not necessarily enhance overall signaling activity 
unless the cognate ligand is also overexpressed. Based 
on our previous studies, we hypothesized that cell-cell 
contacts between adjacent ovarian cancer cells elicit 
Notch3 signaling which in turn upregulates its ligand, 
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Fig. 1: Notch3 knockdown suppresses Jagged1 expression in ovarian cancer cell lines. 
A. Quantitatively RT-PCR performed in OVCAR3 and OVMANA cells demonstrates that Jagged1 and Hes1
transcript levels decrease after Notch3 knockdown by shRNA. B. Western blot demonstrates Jagged1 protein
down-regulation after treating cells with Notch3 shRNA. Protein expression of GAPDH determined by Western
blot is used as the loading control.  
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Jagged1, thus maintaining long-term Notch3 signaling 
in cancer cells. 
To test this hypothesis, we used both reverse and 
forward approaches, based on gene knockdown and 
ectopic expression systems, respectively, to 
demonstrate that Notch3 signaling can regulate 
expression levels of its own ligand, Jagged1. 
Furthermore, because the Wnt/β-catenin pathway has 
been shown to affect Jagged1 expression in hair 
follicles [9], we also determined if Jagged1 could be 
regulated by the Wnt/β-catenin pathway in ovarian 
cancer cells.   
  
RESULTS 
 
To demonstrate whether Notch3 signaling is 
essential for Jagged1 expression, we compared Jagged1 
mRNA and protein levels between ovarian cancer cells 
transfected with Notch3 specific shRNAs and control 
shRNA. Different ovarian cancer cell lines were tested, 
and OVCAR3 and OVMANA ovarian cancer cell lines 
were used because both cell lines expressed abundant 
endogenous Notch3 and Jagged1. Transfection of both 
OVCAR3 and OVMANA with Notch3 specific 
shRNAs resulted in a decrease in the transcript level of 
Notch3, Hes1 (an established Notch regulated gene), 
and Jagged1. Similarly, Western blot analysis 
demonstrated that Notch3 shRNAs robustly suppressed 
protein expression of Jagged1 as well as Notch3. The 
results from a representative shRNA are shown in 
Figure 1. To confirm that blocking expression of 
Notch3 is the main cause for the reduced Jagged1 
expression, we used two additional approaches. First, 
we employed shRNAs targeting RBPjk, a gene that is 
critical in regulating transcription activity of the Notch 
signaling pathway, and second, we applied gamma 
secretase inhibitor (GSI), which blocks cleavage of 
Notch3, thus preventing generation of NICD3. RBPjk 
shRNA treatment decreased the expression of Jagged1 
at both transcript and protein levels in ovarian cancer 
cells (Fig. 2A). Moreover, cell growth was 
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Fig. 2: Downregulation of Jagged1 after knockdown of RBP-jκ, a mediator of the Notch3
signaling pathway, in OVCAR3 cells.  
A. Both Jagged1 mRNA level (left panel) and protein level (right panel) decreased after RBP-jκ knockdown in
OVCAR3 cells as detected by quantitative RT-PCR and Western blot analyses. B. Cell proliferation significantly
decreases in OVCAR3 cells following RBP-jκ knockdown. RBP-jκ shRNA1 and shRNA was co-applied in this
study. C. mRNA expression level of Notch3 is not altered by Jagged1 shRNA knockdown in OVCAR3 cells. 
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significantly decreased in cells transfected with RBPjk 
shRNA (Fig. 2B), a result similar to that obtained by 
inactivating the Notch3 pathway using Notch3 gene 
knockdown and GSI [6]. GSI treatment also 
significantly reduced the transcript levels of Jagged1 
and Hes1, a well-known target gene of Notch receptor 
(supplementary Fig. 1). These results provide evidence 
that Notch3 signaling activity regulates Jagged1 
expression in ovarian cancer cells. In contrast, we did 
not observe a significant effect on the expression level 
of Notch3 by knocking down Jagged1, suggesting a 
“one-way” regulatory loop between Notch3 and 
Jagged1 in ovarian cancer cells (Fig. 2C).   
Next, using two independent approaches, we asked 
whether activation of the Notch3 pathway was 
sufficient to upregulate Jagged1 expression. First, 
IOSE80pc, a cell line derived from normal ovarian 
surface epithelium, was transfected with NICD3 
retrovirus. This cell line represents the benign 
counterpart of ovarian carcinoma and expresses an 
undetectable level of NICD3. As shown in Figure 3A, 
IOSE-80pc cells transduced with NICD3 retrovirus 
expressed abundant NICD3 and expressed a 
significantly higher level of Jagged1 protein than the 
cells transduced with control virus. In addition, we also 
observed an increase in the expression of Jagged1 CTF, 
the activated form of Jagged1 in NICD3-transduced 
cells as compared to control virus-transduced cells. We 
further used Notch3 knockin mice to support the above 
findings. The Cre/Lox Notch3 knockin mouse was 
generated by inserting a Cre/Lox construct carrying 
full-length human Notch3 into the Rosa26 locus (Fig. 
4A). Primary cultures of ovarian surface epithelial 
(OSE) and fallopian tube (FT) epithelial cells were 
established from the Notch3 knockin mouse. When 
Notch3 expression was induced after Ad-Cre infection 
(Fig 4C & D), we found that Jagged1 transcript and 
protein level were elevated as compared to the same 
cells infected with Ade-GFP control virus. The 
expression of a Notch3 target gene, Hes1, was also 
elevated in cells with induced Notch3 expression, 
indicating that the Notch signaling pathway was 
elevated.  
Because the Wnt/β-catenin signaling pathway has 
been reported to affect the expression of Jagged1 in 
hair follicles [9], we determined if this effect occurred 
in cancer cells. shRNAs targeting β-catenin and TCF-4 
were used to inactivate the Wnt/β-catenin pathway in 
OVCAR3 cells. As shown in Figure 5, the shRNAs 
effectively reduced the transcript levels of β-catenin 
and TCF-4, respectively. More importantly, Jagged1 
and several well-established Wnt regulated 
downstream genes including CCND1, SOX9, and 
CD44 were also found to be downregulated. Next, we 
knocked down both Notch3 and β-catenin in OVCAR3 
cells and found that this reduced the Jagged1 transcript 
level significantly more than knockdown of either 
Notch1 or β-catenin alone at the same concentration of 
shRNA plasmid (p<0.001) (Fig. 6). Similarly, cell 
proliferation and colony formation potency in cells 
transduced by both Notch3 shRNA and β-catenin 
shRNA were significantly reduced compared to cells 
transduced by either of shRNA virus alone (p<0.001, 
Fig. 6 B&C). 
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Fig. 3: Ectopic expression of Notch3
intracellular domain upregulates Jagged-1
expression in human ovarian surface epithelial
cells. 
A. Quantitative real-time PCR shows Jagged1
mRNA upregulation after ectopic expression of
Notch3 intracellular fragment (NICD3) in human
ovarian surface epithelial cells, IOSE-80PC. The
expression of a Notch-regulated target gene, Hes1,
is used as a control. B. Western blot demonstrates
that both Jagged1 full length (FL) and C-Terminal
Fragment (CTF) are upregulated after ectopic
expression of NICD3 in IOSE-80PC cells. GAPDH
is used as the loading control.  
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DISCUSSION 
 
Maintaining optimal stoichiometry of ligand and 
receptor interaction is critical for constitutive activation 
of many signal transduction pathways involving 
ligand-receptor binding. In this study, we have 
provided new evidence that Notch3 activation 
enhances the expression level of its ligand, Jagged1, a 
finding that has not been previously reported in cancer 
cells. The presence of a positive regulatory loop helps 
explain why Jagged1 is co-upregulated with Notch3 in 
ovarian serous carcinoma tissues in which gene 
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Fig. 4: Notch3 induction increases Jagged1 expression at both mRNA and protein levels in
Notch3
 knockin mouse cells. 
A. Generation of inducible knockin mice to express human Notch3. Gene targeting strategy is illustrated. The
Notch3 transgene was recombined into the ROSA26 locus of embryonic stem cells.  The targeted of the locus
results in a stop/polyA cassette that prevents expression in the absence of Cre recombinase. The Cre/Lox
reaction (bottom) activates expression of the Notch3 cassette. B. Genotypes of Notch3 knockin mouse. The
band at 340 bp corresponds to the presence of knockin 
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Fig. 5: Wnt signaling pathway supports Jagged1 expression in ovarian cancer cells.  
Quantitative real time PCR shows a significant decrease in Jagged1 expression level after knockdown of either
-catenin (left panel) or TCF4 (right panel) in OVCAR3 cells. Well-known WNT targets including CCND1, SOX9,
and CD44 are used as positive controls.  
β  
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amplification is detected in the Notch3 locus but not in 
the Jagged1 locus. Furthermore, we also demonstrated 
that the Wnt/β-catenin pathway was essential to 
regulate Jagged1 expression, indicating that Jagged1 
expression is regulated by at least two signaling 
pathways in ovarian carcinoma. The results from this 
study have several biological implications relevant to 
the study of the pathogenesis of ovarian cancer.   
Using multiple approaches, including gene 
knockdown in ovarian cancer cells, ectopic expression 
in human OSE cells and induced Notch3 expression in 
mouse OSE and fallopian tube cells, we demonstrated 
that Notch3 signaling was essential and sufficient to 
upregulate Jagged1 expression. Although Notch 
signaling has been reported to increase levels of 
Jagged1 in NIH3T3 cells [10], the current report is the 
first to demonstrate that a similar phenomenon occurs 
in cancer cells. The biological significance of a 
Jagged1/Notch3 positive auto-regulatory loop in cancer 
cells is open to question. It is well-known that Notch 
signaling is involved in embryonic organ development 
and adult tissue differentiation/regeneration [11]. 
Studies from C. elegans and Drosophila suggest a role 
of Notch signaling in lateral inhibition or lateral 
specification. For example, during sensory organ 
development, precursor cells express both Notch 
receptor and its ligand Delta in the same cells; 
however, in adult tissue, Notch receptor and ligand are 
expressed by different tissue types [12]. In the 
tumorigenesis of human cancer, findings by us and 
others have demonstrated that a significant number of 
ovarian, prostate, and lung carcinomas co-express both 
Notch receptor and ligand [8, 13, 14]. This indicates 
either that tumor is derived from a small number of 
precursor cells which co-express both Notch receptor 
and ligand, or that during tumor development cancer 
cells may deregulate the tight control of gene 
expression to permit expression of both Notch receptor 
and ligand in the same cell. Nevertheless, a positive 
auto-regulatory loop supports co-expression of Notch 
and its ligand is likely to amplify or sustain Notch3 
signaling activation, thus providing a long-term 
survival advantage for tumor cells. Because Jagged1 
has been known to participate in vascular development 
[15], it would be interesting to determine if this 
positive regulatory loop in cancer cells is also involved 
in promoting vasculogenesis in the tumor 
microenvironment.   
This report also demonstrated that the Wnt/β-
catenin pathway may serve as a second pathway to 
ensure robust expression of Jagged1 in some ovarian 
serous carcinomas. Evidence that the Wnt signaling 
pathway regulates Jagged1 expression has been 
reported previously in progenitor cells and in colorectal 
cancer cells [16, 17]. Jagged1 was shown to be a direct 
target gene of β-catenin/TCF. The Jagged1 promoter 
contains two TCF consensus binding sites, and specific 
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Fig. 6: Simultaneous knockdown of both
Notch3 and Wnt singling pathways in
ovarian cancer cells.  
A. Simultaneous knockdown of both Notch3 and β-
catenin in OVCAR3 cells reduces Jagged1
transcript level significantly more than knockdown
of either Notch3 shRNA or β-catenin shRNA alone
at the same concentration of shRNA plasmid
(p<0.001). B. Cellular proliferation in OVCAR3 cells
transduced by both Notch3 shRNA and β-catenin
shRNA is significantly lower than in cells
transduced by either shRNA virus alone (p<0.001).
C. Colony formation assay performed in OVCAR3
cells demonstrates that cells transduced by both
Notch3 shRNA and β-catenin shRNA have lower
colony formation ability than cells transduced by
either shRNA virus alone (p<0.001).  
  
www.impactjournals.com/oncotarget    216      Oncotarget 2010; 1: 210-218 
 
binding of β-catenin to this locus was demonstrated by 
ChIP. In findings similar to ours, suppressing the Wnt 
signaling pathway by dominant-negative TCF or small 
molecular inhibitor for β-catenin results in reduced 
Jagged1 expression. Our findings further suggest that 
regulation of Jagged1 expression by Wnt signaling is 
probably a common phenomena shared by most 
epithelial cancer cells.  
Ovarian cancer has dual signaling pathways to 
control Jagged1 expression indicates the importance of 
maintaining active Notch signaling in epithelial cancer 
cells. In addition, the regulation of Jagged1 expression 
by both Wnt/β-catenin and Notch3 pathways may have 
a biological effect beyond being engaged in activating 
Notch3 pathway. Jagged1 may have signaling 
functions that are independent of the canonical Notch 
pathway. It has been demonstrated that upon binding to 
Notch receptor, Jagged1 is sequentially processed by α- 
and γ-secretase, leading to the release of the nuclear 
signaling fragment of Jagged1 [18, 19]. Similar to 
Notch, the soluble Jagged1 intracellular fragment 
translocates into the nucleus and activates gene 
expression via the transcription factor AP1 [18]. The 
putative Notch-independent role for Jagged1 in human 
neoplasms is not clear, and our results did not 
demonstrate that Jagged1 upregulation affected the 
expression level of Notch3, suggesting that the auto-
regulatory loop was “one way”—from Notch3 to 
Jagged1. Interestingly, we observed that the Jagged1 
intracellular domain fragment increased much more 
than did total Jagged1 in OSE cells after transduction 
with NICD3. Further investigation into the function of 
the Jagged1 intracellular domain fragment will be 
necessary to delineate any putative Notch-independent 
function of Jagged1 in cancer cells.  
In summary, this study provides evidence for a dual 
regulation of Jagged1 expression by Wnt and Notch 
signaling pathways in ovarian cancers. These results 
suggest that combinatorial therapy targeting both 
Notch and Wnt pathways may prove to be more 
effective than a single agent for treatment of epithelial 
cancers.  
 
MATERIALS AND METHODS 
 
Quantitative real-time PCR  
 
Relative mRNA transcript expression levels were 
measured by quantitative real-time PCR using a 
previously described method. The primer sequences are 
listed in supplementary Table S1. Average fold 
changes
  were calculated by differences in threshold 
cycles (Ct) between
 pairs of samples to be compared. 
The  β-amyloid precursor gene
  (APP)
  was used for 
normalizing the cDNA concentration of each sample. 
 
Western blot analysis 
 
Protein lysates were prepared by resuspending
 cell 
pellets in Laemmli sample buffer containing 5% β-
mercaptoethanol.
 Protein lysates were separated by 4% 
to 12% or 4% to 20% Tris-glycine gel
 electrophoresis 
and transferred to polyvinylidene difluoride
 membranes 
using a semidry apparatus (Bio-Rad). Antibodies used 
in this study
  include anti-NICD3 (Santa Cruz 
Biotechnology), anti-Jagged1 (Santa Cruz
 
Biotechnology). After incubation with horseradish 
peroxidase (HRP)-conjugated secondary antibody, 
signals were examined by enhanced 
chemiluminescence solution (Thermo Scientific). 
 
Generation of shRNA lentivirus 
 
Notch3, RBPj-k, β-catenin, and TCF4 small hairpin 
RNA(shRNA) were purchased from Sigma-Aldrich. 
Notch3 shRNA4 template (CCGGCCAATGCCAACT 
GAAGAGGATCTCGAGATCCTCTTCAGTTGCAT
TGGTTTTT); Notch3 shRNA5 template (CCGGCCA 
GTTCACCTGTATCTGTATCTCGAGTACAGATAC
AGGTGAACTGGTTTTT); Jagged1 shRNA1 template 
(CCGGCCGAATGGAGTACATCGTATACTCGAGT
ATACGATGTACTCCATTCGGTTTTTG); Jagged1 
shRNA2 template (CCGGCCAGGATAACTGTGCGA 
ACATCTCGAGATGTTCGCACAGTTATCCTGGTT
TTTG); RBPjk shRNA1 template 
(CCGGGCTGGAATACAAGTTGAACAACTCGAG
TTGTTCAACTTGTATTCCAGCTTT TT); RBPjk 
shRNA3 template (CCGGGCACAGATAAGGCAGA 
GTATACTCGAGTATACTCTGCCTTATCTGTGCT
TTTT);  β-catenin shRNA3 template 
(CCGGCCTTTAGCTGTATTGTCTGAACTCGAGT
TCAGACAATACAGCTAAAGGTTTTT);  β-catenin 
shRNA5 template (CCGGCCATTGTTTGTGCA 
GCTGCTTCTCGAGAAGCAGCTGCACAAACAAT
GGTTTTT); TCF4 shRNA2 template 
(CCGGGCAGACATCAATTCCAGTCTTCTCGAGA
AGACTGGAATTGATGTCTGCTTTTT); TCF4 
shRNA3 template (CCGGCGAATTGAAGATCGTTT 
AGAACTCGAGTTCTAAACGATCTTCAATTCGTT
TTT) were cloned into pLKO.1 vector respectively. 
The packaging plasmid psPAX2 and envelope plasmid 
pMD2.G were co-transfected with shRNA plasmid into  
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293FT cells for lentivirus generation. Supernatants 
from the 293FT culture were harvested for lentivirus 
two days after transfection and were used to transduce 
ovarian cancer cells. 
 
Production of NICD3 retroviruses 
 
The NICD3 plasmid expressing the active 
intracellular fragment of Notch3 [20] and was cloned 
into pBabe retrovirus backbone with V5 tag. Packaging 
cells (Phoenix cells) were transiently transfected with 
NICD3 or empty vector using lipofectamine method 
(Invitrogen). Two days later, the viral supernatant was 
collected and polybrene was added to 8 µg/mL for 
retrovirus transduction.  
 
Cell growth and colony formation assays  
 
Cells were grown in 96-well plates at a density of 
5,000 per well. Cell number was measured by the 
incorporation of SYBR green I nucleic acid gel stain 
(Molecular Probes) using a fluorescence microplate 
reader (Fluostar from BMG). Data were determined 
from five replicates at different time points. For colony 
formation assay, cells were seeded into 25-cm2 flasks 
at a cell density of 2,000 cells per flask. After two 
weeks, colonies were stained with crystal violet 
(Sigma) and counted. 
 
Generation of Notch3 inducible mice 
 
Human full-length Notch3 cDNA was inserted into 
the ROSA26 locus in embryonic stem cells by 
homologous recombination [21]. Notch3 was first 
cloned into pBIG-T and shuttled into pROSA26PA 
[21] prior to transfection into ES cells.  The targeted 
locus includes a 5’ floxed stop/polyA cassette fused to 
the expression cassette; the floxed cassette prevents 
expression in the absence of Cre recombinase. The 
Cre/Lox reaction activates expression of the Notch3 
cassette. The primer sequences for genotyping were: 
forward 5’-CAGCTGTCACAGCCGATGCCC-3’, 
reverse: 5’-AGCAGCTTGGCAGCCTCATAG 
C-3’, which will amplify a 340 band for Notch3 
knockin allele. The ROSA locus primers are forward 
5’-CGTGATCTGCAACTCCAGTC-3’, reverse 5’-
GGAGCGGGAGAAATGGATATG-3’, which will 
amplify a 425 bp band in wildtype allele, but will not 
produce a PCR product in knockin allele since this 
locus is disrupted. Control primers that amplify TCRD 
locus were: forward 5’- CAAATGTTGCTTGTC 
TGGTG-3’, reverse 5’- GTCAGTCGAGTGCACAGTTT-
3’. 
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